Wall Street Pummels ADVM After Recent Earnings Report

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) went up by 6.81% from its latest closing price compared to the recent 1-year high of $26.98. The company’s stock price has collected 9.39% of gains in the last five trading sessions. Press Release reported on 09/10/20 that Adverum Biotechnologies to Participate in the Cantor Virtual Global Healthcare Conference

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Is It Worth Investing in Adverum Biotechnologies, Inc. (NASDAQ :ADVM) Right Now?

Plus, the 36-month beta value for ADVM is at 1.64. Opinions of the stock are interesting as 8 analysts out of 9 who provided ratings for Adverum Biotechnologies, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 1 as “sell.”

The average price from analysts is $28.43, which is -$12.7 below the current price. ADVM currently public float of 55.83M and currently shorts hold a 16.20% ratio of that float. Today, the average trading volume of ADVM was 1.36M shares.

ADVM’s Market Performance

ADVM stocks went up by 9.39% for the week, with a monthly jump of 1.52% and a quarterly performance of -46.41%, while its annual performance rate touched 119.72%. The volatility ratio for the week stands at 5.62% while the volatility levels for the past 30 days are set at 5.48% for Adverum Biotechnologies, Inc.. The simple moving average for the period of the last 20 days is 2.24% for ADVM stocks with a simple moving average of -12.77% for the last 200 days.

Analysts’ Opinion of ADVM

Many brokerage firms have already submitted their reports for ADVM stocks, with Raymond James repeating the rating for ADVM by listing it as a “Underperform.” The predicted price for ADVM in the upcoming period, according to Raymond James is $20 based on the research report published on June 26th of the current year 2020.

RBC Capital Mkts, on the other hand, stated in their research note that they expect to see ADVM reach a price target of $24. The rating they have provided for ADVM stocks is “Outperform” according to the report published on May 13th, 2020.

SunTrust gave a rating of “ Buy” to ADVM, setting the target price at $21 in the report published on May 5th of the current year.

ADVM Trading at -19.28% from the 50-Day Moving Average

After a stumble in the market that brought ADVM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.93% of loss for the given period.

Volatility was left at 5.48%, however, over the last 30 days, the volatility rate increased by 5.62%, as shares sank -4.44% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.00% lower at present.

During the last 5 trading sessions, ADVM rose by +9.39%, which changed the moving average for the period of 200-days by +17.92% in comparison to the 20-day moving average, which settled at $12.39. In addition, Adverum Biotechnologies, Inc. saw 10.24% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ADVM starting from Soparkar Peter, who bought 7,692 shares at the price of $13.00 back on Aug 17. After this action, Soparkar Peter now owns 10,692 shares of Adverum Biotechnologies, Inc., valued at $99,996 using the latest closing price.

Fischer Laurent, the CEO and Director of Adverum Biotechnologies, Inc., bought 7,692 shares at $13.00 during a trade that took place back on Aug 17, which means that Fischer Laurent is holding 7,692 shares at $99,996 based on the most recent closing price.

Stock Fundamentals for ADVM

Current profitability levels for the company are sitting at:

  • -27418.00 for the present operating margin

The net margin for Adverum Biotechnologies, Inc. stands at -25794.40. The total capital return value is set at -33.53, while invested capital returns managed to touch -31.87. Equity return is now at value -37.70, with -31.50 for asset returns.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Based on Adverum Biotechnologies, Inc. (ADVM), the company’s capital structure generated 18.55 points at debt to equity in total, while total debt to capital is 15.64.

Related Articles

We Analyzed the Future Direction of Dolby Laboratories Inc. (DLB), Here is What We Found

Dolby Laboratories Inc. (NYSE:DLB) went down by -1.50% from its latest closing price compared to the recent 1-year high of $73.94. The company’s stock...

Can Southwest Airlines Co. (LUV) Remain Competitive?

Southwest Airlines Co. (NYSE:LUV) went down by -1.50% from its latest closing price compared to the recent 1-year high of $58.83. The company’s stock...

Is There a Dimmer Outlook Ahead for New Residential Investment Corp.?

New Residential Investment Corp. (NYSE:NRZ) went down by -2.99% from its latest closing price compared to the recent 1-year high of $17.66. The company’s...

Latest Posts

We Analyzed the Future Direction of Dolby Laboratories Inc. (DLB), Here is What We Found

Dolby Laboratories Inc. (NYSE:DLB) went down by -1.50% from its latest closing price compared to the recent 1-year high of $73.94. The company’s stock...

Can Southwest Airlines Co. (LUV) Remain Competitive?

Southwest Airlines Co. (NYSE:LUV) went down by -1.50% from its latest closing price compared to the recent 1-year high of $58.83. The company’s stock...

Is There a Dimmer Outlook Ahead for New Residential Investment Corp.?

New Residential Investment Corp. (NYSE:NRZ) went down by -2.99% from its latest closing price compared to the recent 1-year high of $17.66. The company’s...

Analog Devices Inc. (ADI): Skating on Thin Ice? We Know the Answer

Analog Devices Inc. (NASDAQ:ADI) went down by -1.92% from its latest closing price compared to the recent 1-year high of $127.39. The company’s stock...

Is Gilead Sciences Inc. (GILD) a Keeper?

Gilead Sciences Inc. (NASDAQ:GILD) went down by -0.49% from its latest closing price compared to the recent 1-year high of $85.97. The company’s stock...